Obagi Medical Partners with Aesthetic Record for Real-World Evidence on saypha® MagIQ™
Event summary
- Obagi Medical, part of Waldencast plc (NASDAQ: WALD), has partnered with Aesthetic Record for the ALOHA Program to gather real-world evidence on its saypha® MagIQ™ injectable.
- Aesthetic Record’s platform, used by 9,000+ clinics, will facilitate data collection and analysis across multiple trials and evaluation programs.
- Initial findings from the program will be presented at the Aesthetic Next conference in 2026.
- saypha® MagIQ™ leverages MACRO Core Technology for stable hyaluronic acid matrix delivery.
The big picture
This collaboration underscores a growing trend in aesthetic medicine where real-world data is increasingly used to validate clinical efficacy and drive product adoption. By leveraging Aesthetic Record’s technology, Obagi aims to streamline its launch strategy and strengthen patient-provider relationships through standardized protocols and outcomes tracking.
What we're watching
- Data Integration
- How effectively Aesthetic Record’s platform can capture and analyze real-world data to support Obagi’s product claims.
- Market Adoption
- The pace at which saypha® MagIQ™ gains traction among aesthetic clinics, particularly those already using Aesthetic Record.
- Competitive Positioning
- Whether Obagi can differentiate itself in the crowded hyaluronic acid injectables market through this evidence-driven approach.
Related topics